磷脂脂质体与催乳素分泌：对自发性和药物性高催乳素血症的影响

Phospholipid liposomes and prolactin secretion: effects on spontaneous and drug-induced hyperprolactinaemia.

作者信息

Falaschi P, Rocco A, D'Urso R, Jellamo R, Toffano I, Frajese G

出版信息

Life Sci. 1982 Jul 5;31(1):17-23. doi: 10.1016/0024-3205(82)90395-2.

Abstract

Bovine brain phospholipid liposomes (BC-PL) reduce plasma prolactin (PRL) levels in humans after acute administration and counteract the metoclopramide- and sulpiride-induced hyperprolactinaemia. However, BC-PL, like nomifensine, a dopamine (DA) reuptake inhibitor and therefore an indirect dopaminergic compound, does not influence TRH-induced hyperprolactinaemia. Moreover, BC-PL and nomifensine reduce plasma PRL levels in hyperprolactinaemic PCO syndromes but not in PRL secreting pituitary adenomas. The results obtained indicate that BC-PL antagonizes the DA blockade-induced hyperprolactinaemia and that the main site of action of BC-PL seems to be at the hypothalamic level; however a concomitant pituitary effect cannot be ruled out.

摘要

牛脑磷脂脂质体（BC-PL）在急性给药后可降低人体血浆催乳素（PRL）水平，并可对抗甲氧氯普胺和舒必利诱导的高催乳素血症。然而，BC-PL与诺米芬辛（一种多巴胺（DA）再摄取抑制剂，因此是一种间接多巴胺能化合物）一样，并不影响促甲状腺激素释放激素（TRH）诱导的高催乳素血症。此外，BC-PL和诺米芬辛可降低高催乳素血症多囊卵巢综合征患者的血浆PRL水平，但对分泌PRL的垂体腺瘤患者无效。所得结果表明，BC-PL可拮抗DA阻断诱导的高催乳素血症，且BC-PL的主要作用部位似乎位于下丘脑水平；然而，不能排除垂体的协同作用。